Pair page
ARA-290 with BPC-157
Mechanism-tag overlap and published literature for ARA-290 and BPC-157, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
epo-derivedinnate-repair-receptor-agonist
cytoprotectiontissue-repair
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying ARA-290 and BPC-157 have published these mechanism-level observations. Not a co-administration recommendation.
BPC-157 promotes angiogenesis and tissue repair through VEGFR2-Akt-eNOS and related pathways; ARA-290 engages the IRR for small-nerve-fiber regeneration. Combined, they address complementary repair systems — vascular / connective tissue (BPC-157) and small-fiber neural (ARA-290) — particularly relevant in diabetic complications.
Quick facts
ARA-290
BPC-157
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2020 | ARA-290 | Brines M, Dunne A, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Cibinetide (ARA 290) for treatment of sarcoidosis-associated chronic neuropathic pain: A randomized, double-blind, placebo-controlled study. Clin Immunol. 2020;… PMID 31982580 | human trial, Phase 2 |
| 2015 | ARA-290 | Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol… PMID 25387363 | human trial, Phase 2 |
| 2013 | ARA-290 | Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19:33… PMID 24100673 | human trial, Phase 2 |
| 2012 | ARA-290 | Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-1436.… PMID 23168581 | human trial |
| 2019 | ARA-290 | Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2019;60(2):5… | human study |
| 2017 | ARA-290 | Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and ne… PMID 28475703 | human study |
| 2011 | ARA-290 | Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology. 201… PMID 21966093 | preclinical, in vivo |
| 2012 | ARA-290 | Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012;18(1):486-496. PMID: 22183892. (Key mechanistic review of the Innate Repair Receptor.) PMID 22183892 | review |
| — | ARA-290 | ClinicalTrials.gov. Search: "cibinetide" / "ARA-290" / "ARA 290". Multiple NCT records across sarcoidosis, diabetic neuropathy, chronic pain, renal protection, islet transplantation. | regulatory / registry |
| 2016 | ARA-290 | Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Bränström R. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation. 2016;100(3):554-562. PMID: 26840669. PMID 26840669 | research article |
| 2016 | ARA-290 | Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the Innate Repair Receptor to Treat Neuropathy. Pain Rep. 2016;1(1):e566. PMID: 29392186. PMID 29392186 | research article |
| 2015 | ARA-290 | Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015;151:32-40. PMID: 25783068. PMID 25783068 | research article |
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
Related pair pages
More research context
Frequently asked
Have ARA-290 and BPC-157 been studied together?
Researchers have published mechanistic-level co-administration discussion of ARA-290 and BPC-157. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do ARA-290 and BPC-157 share?
ARA-290 and BPC-157 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of ARA-290 and BPC-157?
ARA-290: Not approved (orphan designation for sarcoidosis). BPC-157: Category 2 (reclassification pending). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on ARA-290 and BPC-157?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the ARA-290 profile and the BPC-157 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026